Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Cyclophosphamide 45fludarabine phosphate 39Peripheral Blood Stem Cell Transplantation 36Busulfan 34Antilymphocyte Serum 26Tacrolimus 25Cyclosporine 25Methotrexate 23Filgrastim 23Mycophenolic Acid 22Radiotherapy 21Melphalan 17Etoposide 15Cytarabine 15Whole-Body Irradiation 14Methylprednisolone 13Cord Blood Stem Cell Transplantation 12Biopsy 9Azacitidine 9Specimen Handling 8ruxolitinib 7Sirolimus 7Flow Cytometry 7Cyclosporins 7Alemtuzumab 7Thiotepa 6Psychiatric Rehabilitation 6Decitabine 6sargramostim 5Rituximab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × axatilimab × Myeloid × Clear all
NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡